Autolus Stock Jumps On Cancer mRNA Therapeutics Agreement With Moderna

Autolus Therapeutics plc AUTL has granted Moderna Inc MRNA an exclusive license to develop and commercialize mRNA therapeutics incorporating Autolus' proprietary binders for up to four immuno-oncology targets.
Autolus would be eligible to receive an upfront payment for each target licensed by Moderna and milestone payments.
In addition, Autolus would be entitled to receive royalties on net sales.
Price Action: AUTL shares are up 16.9% at $6.22, while MRNA stock is +2.1% at $360.95 during the premarket session on the last check Monday.